RNA - Avidity Biosciences Inc
IEX Last Trade
43.93
1.290 2.936%
Share volume: 1,094,696
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$42.64
1.29
3.03%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-02-28 | 2023-05-09 | 2023-08-08 | 2023-11-08 | 2024-02-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 420.801 M | 430.539 M | 638.800 M | 613.976 M | 610.784 M | 573.163 M | 628.555 M | 951.474 M | |
| Current Assets | 404.251 M | 414.464 M | 622.942 M | 597.147 M | 594.534 M | 555.487 M | 611.307 M | 934.474 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 6.033 M | 8.916 M | 12.215 M | 10.847 M | 18.031 M | 12.904 M | 15.956 M | 18.601 M | |
| Short Term Investments | 6.033 M | 8.916 M | 12.215 M | 10.847 M | 18.031 M | 12.904 M | 15.956 M | 18.601 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 398.218 M | 405.548 M | 610.727 M | 586.300 M | 576.503 M | 542.583 M | 595.351 M | 915.873 M | |
| Total Non-current Assets | 16.550 M | 16.075 M | 15.858 M | 16.829 M | 16.250 M | 17.676 M | 17.248 M | 17.000 M | |
| Property Plant Equipment | 6.137 M | 6.037 M | 6.254 M | 7.845 M | 7.776 M | 8.130 M | 8.381 M | 8.655 M | |
| Other Assets | 10.162 M | 9.787 M | 9.353 M | 8.733 M | 8.179 M | 9.251 M | 8.572 M | 8.050 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 420.801 M | 430.539 M | 638.800 M | 613.976 M | 610.784 M | 573.163 M | 628.555 M | 951.474 M | |
| Total liabilities | 46.450 M | 53.557 M | 60.725 M | 55.061 M | 51.606 M | 55.695 M | 127.791 M | 120.575 M | |
| Total current liabilities | 33.687 M | 42.666 M | 51.908 M | 48.085 M | 45.244 M | 48.716 M | 80.680 M | 74.955 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 4.010 M | 2.706 M | 1.235 M | 0.000 | 0.000 | 0.000 | 40.898 M | 40.199 M | |
| Current long term debt | 3.068 M | 3.090 M | 3.105 M | 3.129 M | 3.151 M | 3.602 M | 3.639 M | 3.726 M | |
| Long term debt | 8.753 M | 8.185 M | 7.582 M | 6.976 M | 6.362 M | 6.979 M | 6.213 M | 5.421 M | |
| Other liabilities | 4.010 M | 2.706 M | 1.235 M | 0.000 | 0.000 | 0.000 | 40.898 M | 40.199 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 374.351 M | 376.982 M | 578.075 M | 558.915 M | 559.178 M | 517.468 M | 500.764 M | 830.899 M | |
| Common stock | 49.927 M | 53.069 M | 57.406 M | 70.433 M | 71.390 M | 74.097 M | 76.128 M | 87.212 M | |
| Retained earnings | -264.474 M | -308.073 M | -358.544 M | -410.938 M | -457.963 M | -510.321 M | -570.764 M | -639.619 M |